SES Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SES is not a good buy right now for an impatient trader. The stock is in a short-term breakdown (down ~9.25% today, trading below near-term support), momentum is weakening, and there are no Intellectia entry signals to justify stepping in immediately. While options positioning is bullish (call-skewed) and hedge funds have been buying, the price/indicator setup suggests a higher probability of near-term downside toward the next support zone before a cleaner entry emerges.
Intellectia Proprietary Trading Signals
Trend/momentum: Bearish-to-weakening. MACD histogram is negative (-0.015) and expanding lower, signaling downside momentum is increasing. RSI(6)=38.1 is not deeply oversold but is weak, consistent with a selloff that may not be finished.
Levels: Current price 2.07 is below S1 (2.091), indicating a support break. Next support is S2 at 1.956. Overhead resistance starts near the pivot 2.312, then R1 2.532.
Moving averages: Converging MAs suggest the stock is not in a strong trend structurally, but today’s sharp drop and MACD behavior tilt the immediate bias bearish.
Quant pattern read-through: Similar candlestick-pattern analysis implies ~80% chance of mild additional drift down next day/week and a larger negative bias over a month (-6.58%), which aligns with the broken-support setup.
with Overweight, citing Molecular Universe traction and ~$200M+ cash runway; BNPP initiated Outperform (note: that coverage refers to SES S.A. with a EUR target, but it still reflects broader positive sector/brand sentiment).
before stabilization.
Latest reported quarter: 2025/Q3.
Growth/quality: Revenue was $7.118M, flat YoY (0.00% YoY), indicating limited top-line acceleration. Profitability: Net loss widened to -$20.92M (down -30.70% YoY), and EPS fell to -$0.06 (down -33.33% YoY), showing deterioration in bottom-line trends. Margins: Gross margin improved/held strong at 51.08% (flat YoY), which is a positive structural sign, but it is not yet translating into narrowing losses.
Overall: Financials read as “high-potential but not yet operating leverage,” which is typically not supportive of chasing a falling chart without a clear entry signal.
Recent analyst trend: Net positive.
• 2025-11-06: Cantor Fitzgerald reiterated Overweight and raised PT to $4 (from $2), citing early traction of Molecular Universe with multiple OEMs and cash runway to commercialization. • 2025-12-18: BNPP initiated Outperform with EUR 7.20 PT (note: stated as SES S.A.; treat as adjacent/related coverage rather than a direct SES AI U.S. PT).
Wall Street pros: commercialization pathway, partner/OEM adoption narrative, and cash runway. Wall Street cons: execution risk (commercialization timing), ongoing and worsening losses, and the stock’s extreme volatility (making timing critical).
